With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...

Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

NVIDIA-BACKED Recursion Pharmaceuticals said on Tuesday (Sep 3) its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...

REC-3964 is designed to treat C. diff by selectively inhibiting the glucosyltransferase activity of toxin B produced by the bacterium in the gastrointestinal tract.

GlobeNewswire Press Release.Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary ...